Medical nanofiber technology to prevent cerebrospinal leakage in neurosurgeries

Introduction

Cerebrospinal fluid (CSF) leaks are a major post-neurosurgical complication that occurs in 4% to 32% of neurosurgeries, depending on the surgical site. It impacts millions globally, causing life-threatening infections and costing the EU an estimated €330 million each year.

Problem Statement

Prevention requires proper sealing and healing of the Dura Mater. Current dural repair treatments are suboptimal, leading to:

• Long hospital stays
• Extended recovery
• A high economic burden on healthcare systems

Solution Overview

To address this, Nurami has developed ArtiFix, a bio-absorbable, biocompatible patch designed to seal and repair the dura and prevent CSF leaks.

Key Features of ArtiFix

• Adhesive Layer: Provides sutureless fixation and watertight sealing.
• Electrospun Nanofibers: Promote healing of the dura.
• 3-in-1 Solution: Combines sealing, healing, and adherence to the surgical site, even to wet tissue.

ArtiFix will be the first and only solution of its kind on the market, uniquely combining these features. It represents a new category of suture-less sealing patches targeting dural repair, functioning as both a dura substitute and a sealant patch in a single, easy-to-apply solution.

Market Impact

ArtiFix is set to replace current dural repair products, which include:

1. Dura substitute patches
2. Liquid sealants
3. Sutures

By reducing extra surgeries, hospitalizations, and long-term care, ArtiFix will improve patient outcomes and reduce the costs of cerebrospinal complications.

Future Potential

ArtiFix is a platform adhesive patch that can be fine-tuned for implementation in numerous additional surgical procedures. In this manner, Nurami will capitalize on a large, underserved, and growing multi-billion-dollar market opportunity with significant commercial prospects.

Team and Funding

Nurami has an outstanding multidisciplinary team supported by a strong scientific advisory board and an active board of directors. The company is capital efficient, having achieved preliminary product commercialization for its first product in the pipeline following total funding to date of only €14.8M.